Sea Limited vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Sea Limited trades at $95.7 (market cap $56.89B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: Sea Limited is far larger — about 25.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| SE | SLS | |
|---|---|---|
Market Cap | $56.89B | $2.27B |
Volume | 5,359,457 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $188.00 | $15.46 |
52-Week Low | $78.16 | $1.39 |
Typical Hold Time | 102 Days | — |
Enterprise Value | $51.92B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $95.25, down 0.62% with a bearish technical signal. The company shows strong fundamental improvement with revenue growing from $12.4B in 2022 to $22.9B in 2025, achieving profitability with net income of $1.58B. Analyst consensus remains strongly bullish with 70% buy ratings and a $153.67 price target, though recent insider selling and technical weakness create near-term headwinds. Operating cash flow has turned positive at $5.02B, supporting the company's growth trajectory.
Sea Limited presents a compelling growth story with improving profitability and strong analyst support, though technical weakness and insider selling warrant caution. The stock trades at a discount to analyst targets with solid fundamentals, but investors should monitor execution risks in competitive e-commerce and digital entertainment markets. The current price level near support at $91-92 offers potential entry for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →